Brokerages Set Kura Oncology, Inc. (NASDAQ:KURA) Target Price at $29.86

Kura Oncology, Inc. (NASDAQ:KURA) has earned a consensus rating of “Buy” from the ten research firms that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among analysts that have covered the stock in the last year is $29.86.

KURA has been the topic of several research analyst reports. Stifel Nicolaus cut shares of Kura Oncology from a “buy” rating to a “hold” rating and lowered their price target for the company from $26.00 to $19.00 in a report on Monday, October 14th. StockNews.com lowered shares of Kura Oncology from a “hold” rating to a “sell” rating in a research report on Wednesday, November 20th. Jefferies Financial Group reduced their price objective on shares of Kura Oncology from $32.00 to $28.00 and set a “buy” rating for the company in a research note on Thursday, November 21st. Bank of America cut their target price on Kura Oncology from $36.00 to $29.00 and set a “buy” rating on the stock in a report on Friday, November 22nd. Finally, Lifesci Capital raised Kura Oncology to a “strong-buy” rating in a report on Tuesday, October 22nd.

Hedge Funds Weigh In On Kura Oncology

Large investors have recently added to or reduced their stakes in the company. nVerses Capital LLC bought a new stake in Kura Oncology in the third quarter valued at $25,000. Point72 DIFC Ltd acquired a new stake in shares of Kura Oncology in the third quarter valued at $146,000. Quarry LP acquired a new position in Kura Oncology during the 2nd quarter worth about $196,000. Erste Asset Management GmbH bought a new stake in Kura Oncology during the 3rd quarter worth about $215,000. Finally, Bellevue Group AG increased its position in Kura Oncology by 36.0% in the 3rd quarter. Bellevue Group AG now owns 13,600 shares of the company’s stock valued at $266,000 after acquiring an additional 3,600 shares in the last quarter.

Kura Oncology Stock Performance

KURA stock opened at $8.71 on Monday. The firm has a 50 day simple moving average of $12.83 and a 200 day simple moving average of $17.43. Kura Oncology has a 52 week low of $8.42 and a 52 week high of $24.17. The stock has a market cap of $677.32 million, a P/E ratio of -3.69 and a beta of 0.75. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.